“…However, POC assays are still limited in terms of sensitivity and quantitation, when compared to laboratory-based diagnosis, which constrains their application. Commercially available LFA assays (Cholestech (Hayward, CA, USA), Milenia Biotec (Gießen, Germany), BÜHLMANN (Schönenbuch, Switzerland)) are unable to detect CRP concentrations below 0.2 mg·L −1 [ 83 ]. Efforts have been performed to enhance the performance of LFA tests in CRP detection, by improving the configuration of ELISA based assays (e.g., “capillary ELISA” [ 54 ], three-line LFA [ 13 ] and 3 test-line assay [ 55 ]) incorporating tailored size functionalized Au NPs [ 84 ] or using a combined approach [ 83 ].…”